50 Studies Every Neurologist Should Know presents summaries and analyses of the fifty clinical trials that have shaped the current practice of neurology. Every subspecialty is covered, with special emphasis on neurocritical care and vascular neurology.

Section I: Behavioral Neurology 1. Cholinesterase Inhibitors for Alzheimer's Disease 2. Memantine for Alzheimer's Disease Section II: Epilepsy 3. Lorazepam for Generalized Status Epilepticus 4. Lamotrigine for Partial Epilepsy: Arm A of the SANAD Trial 5. Valproate for Generalized and Unclassifiable Epilepsy: Arm B of the SANAD Trial Section III: Headache 6. Sumatriptan for Acute Migraine Section IV: Neuroinfectious Disease 7. Steroids for Bell's Palsy 8. Steroids for Acute Bacterial Meningitis Section V: Movement Disorders 9. Levadopa for Parkinson's Disease 10. Deep-Brain Stimulation for Parkinson's Disease Section VI: Multiple Sclerosis 11. Oral vs. IV Steroids for Acute Relapses of Multiple Sclerosis 12. Interferon Beta-1a for a First Demyelinating Event: The CHAMPS Trial 13. Glatiramer Acetate for Clinically Isolated Syndrome: The PreCISe Trial 14. Natalizumab for Relapsing Multiple Sclerosis: The SENTINEL Trial 15. Fingolimod for Relapsing Multiple Sclerosis: The TRANSFORMS Trial 16. Oral BG-12 for Relapsing-Remitting Multiple Sclerosis, Part I: The DEFINE Trial17. Oral BG-12 for Relapsing-Remitting Multiple Sclerosis, Part II: The CONFIRM Trial Section VII: Neurocritical Care 18. Therapeutic Hypothermia for Cardiac Arrest, Part I: The HACA Trial 19. Therapeutic Hypothermia for Cardiac Arrest, Part II: The Australian Trial 20. Decompressive Craniectomy for Diffuse Traumatic Brain Injury: The DECRA Trial 21. Nimodipine for Subarachnoid Hemorrhage Section VIII: Neuromuscular Disease 22. IVIG vs. Plasma Exchange for Guillain-Barre Syndrome 23. IVIG vs. Plasma Exchange for Myasthenia Gravis 24. Riluzole for Amyotrophic Lateral Sclerosis Section IX: Neuro-Oncology 25. Radiotherapy Plus Temozolomide for Glioblastoma 26. Methylated MGMT Gene Promoter and Response to Temozolomide for Glioblastoma Section X: Neuro-Ophthalmology 27. Steroids for Acute Optic Neuritis: The Optic Neuritis Treatment Trial Section XI: Neuro-Otology 28. The Epley Maneuver for Benign Paroxysmal Positional Vertigo Section XII: Sleep 29. Modafinil for Narcolepsy 30. Continuous Dopamine Agonist for Restless Legs Syndrome Section XIII: Spine Disorders 31. Early Surgery for Sciatica 32. Surgery for Lumbar Degenerative Spondylolisthesis: The SPORT Trial 33. Steroids vs. No Steroids for Acute Spinal Cord Injury: The NASCIS II Trial Section XIV: Vascular Neurology 34. IV Thrombolysis 3 Hours After an Acute Ischemic Stroke: The NINDS Trial 35. IV Thrombolysis 3 to 4.5 Hours After an Acute Ischemic Stroke: The ECASS III Trial 36. Endovascular Therapy for Acute Ischemic Stroke, Part I (Intra-arterial Thrombolysis): The PROACT II Trial 37. Endovascular Therapy for Acute Ischemic Stroke, Part II (After IV Thrombolysis): The IMS III Trial 38. Endovascular Therapy for Acute Ischemic Stroke, Part III (Using Neuroimaging to Select Patients): The MR RESCUE Trial 39. Endovascular Therapy for Acute Ischemic Stroke, Part IV (Clinical Trial Success): The MR CLEAN Trial 40. Carotid Endarterectomy for Symptomatic High-Grade Carotid Stenosis: The NASCET Trial, Part I 41. Carotid Endarterectomy for Symptomatic Moderate Carotid Stenosis: The NASCET Trial, Part II 42. Carotid Endarterectomy for Asymptomatic Carotid Stenosis: The ACAS Trial 43. Early Aspirin for Acute Ischemic Stroke: The CAST Trial 44. Aspirin vs. Heparin for Acute Ischemic Stroke: The IST Trial 45. Dipyridamole and Asprin for Secondary Stroke Prevention: The ESPS-2 Trial 46. High-Dose Atorvastatin After Stroke or Transient Ischemic Attack: The SPARCL Trial 47. Adjusted-Dose Warfarin for Stroke Prevention in High-Risk Atrial Fibrillation Patients: The SPAF III Trial 48. Dabigatran for Stroke Prevention in Atrial Fibrillation Patients: The RE-LY Trial 49. Apixaban for Stroke Prevention in Atrial Fibrillation Patients: The ARISTOTLE Trial 50. Rivaroxaban for Stroke Prevention in Atrial Fibrillation Patients: The ROCKET AF Trial

Selling point: The first book of its kind to present a collection of detailed, yet easy-to-digest, influential studies in neurology. Selling point: Each chapter begins with a quotation putting the findings in context. Selling point: Each study is complimented by a clinical case which allows readers to apply research findings to real-world situations.

David Y. Hwang is the Assistant Professor of Neurology in the Division of Neurocritical Care and Emergency Neurology at Yale University School of Medicine which is located in New Haven, Connecticut. David M. Greer is the The Zimmerman and Spinelli Professor and Vice Chairman of the Department of Neurology at Yale University School of Medicine which is located in New Haven, Connecticut.

Selling point: The first book of its kind to present a collection of detailed, yet easy-to-digest, influential studies in neurology. Selling point: Each chapter begins with a quotation putting the findings in context. Selling point: Each study is complimented by a clinical case which allows readers to apply research findings to real-world situations.